Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DAL5C7
|
|||
| Drug Name |
Eftilagimod alpha
|
|||
| Synonyms |
IMP321
Click to Show/Hide
|
|||
| Drug Type |
Recombinant?protein
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 2 | [1] | |
| Squamous head and neck cell carcinom [ICD-11: 2D60.0; ICD-10: C77.0] | Phase 2 | [1] | ||
| Company |
Immutep
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03625323) Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.